Vimarsana
Biggest News Aggregation in the World

Page 46 - Human Use News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Human Use. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Human Use Today - Breaking & Trending Today

Solvias to Perform Release Testing on World's First CRISPR-based Gene-Editing Therapy - Vimarsana News

Solvias to Perform Release Testing on World's First CRISPR-based Gene-Editing Therapy

/PRNewswire/ -- Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics, announced today that it will perform analytical release...

Preventing original pharmaceuticals' price decreases in Turkey with partial preliminary injunctions - Vimarsana News

Preventing original pharmaceuticals' price decreases in Turkey with partial preliminary injunctions

Selin Sinem Erciyas, Zeynep Çağla Üstün, and Beste Turan of Gün and Partners explain a decision by the Turkish Civil Court for Intellectual and Industrial Property Rights that set an important precedent for the protection of pharmaceutical patent holders’ rights

NICE recommends new drug for ulcerative colitis that could benefit 25,000 patients - Vimarsana News

NICE recommends new drug for ulcerative colitis that could benefit 25,000 patients

The Pharmaceutical Journal from the Royal Pharmaceutical Society

U.S. FDA Approves Takeda's HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) -January 16, 2024 at 08:10 am EST - Vimarsana News

U.S. FDA Approves Takeda's HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) -January 16, 2024 at 08:10 am EST

HYQVIA [Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase], the Only up to Once Monthly Subcutaneous Immunoglobulin Infusion to Treat CIDP, Can Be Administered by a Healthcare...

Eisai: The Scientific Advisory Group (SAG) to Convene to Discuss the Marketing Authorization Application for lecanemab in the EU -January 11, 2024 at 03:03 am EST - Vimarsana News

Eisai: The Scientific Advisory Group (SAG) to Convene to Discuss the Marketing Authorization Application for lecanemab in the EU -January 11, 2024 at 03:03 am EST

- Eisai Co., Ltd. announced today that the Scientific Advisory Group will convene to discuss the marketing authorization application of lecanemab , which is currently under review by the European...